Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.

V, Skljarevski; TM, Oakes; Q, Zhang; MB, Ferguson; J, Martinez; A, Camporeale; KW, Johnson; Q, Shan; J, Carter; A, Schacht; PJ, Goadsby; DW, Dodick

doi:10.1001/jamaneurol.2017.3859

Public

Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.

Shared by NobleBlocks on Feb 1, 2018 • 12:00 AM UTC

Authors:

Skljarevski V

Oakes TM

Zhang Q

Abstract

<h4>Importance</h4>Galcanezumab (LY2951742), a monoclonal antibody against calcitonin gene-related peptide (CGRP), is one of a novel class of new medicines for migraine prevention.<h4>Objective</h4>To assess whether at least 1 dose of galcanezumab was superior to placebo for episodic migraine preven...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!